Cleavage of zeta PKC but Not lambda /iota PKC by Caspase-3 during UV-induced Apoptosis*

Sonia Frutos, Jorge Moscat, and María T. Diaz-MecoDagger

From the Laboratorio Glaxo Wellcome-CSIC de Biología Molecular y Celular, Centro de Biología Molecular "Severo Ochoa" (Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid), Universidad Autónoma, Canto Blanco, 28049 Madrid, Spain

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The stimulation of caspases is a critical event in apoptotic cell death. Several kinases critically involved in cell proliferation pathways have been shown to be cleaved by caspase-mediated mechanisms. Thus, the degradation of delta  protein kinase C (PKC) and MEKK-1 by caspase-3 generates activated fragments corresponding to their catalytic domains, consistent with the observations that both enzymes are important for apoptosis. In contrast, other kinases reported to have anti-apoptotic properties, such as Raf-1 and Akt, are inactivated by proteolytic degradation by the caspase system. Since the atypical PKCs have been shown to play critical roles in cell survival, in the study reported here we have addressed the potential degradation of these PKCs by the caspase system in UV-irradiated HeLa cells. Herein we show that although zeta PKC and lambda /iota PKC are both inhibited in UV-treated cells, only zeta PKC but not lambda /iota PKC is cleaved by a caspase-mediated process. This cleavage generates a fragment that corresponds to its catalytic domain that is enzymatically inactive. The sequence where caspase-3 cleaves zeta PKC was mapped, and a mutant resistant to degradation was shown to protect cells from apoptosis more efficiently than the wild-type enzyme.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The two members of the atypical protein kinase C (PKC)1 subfamily of isozymes (aPKCs), namely zeta PKC and lambda /iota PKC, have recently been shown to be involved in a number of important cellular functions including cell proliferation and survival (1-5). The mechanisms whereby the aPKCs control these functions most probably involve their ability to regulate ERK-AP1 (6-11) and NF-kappa B (10, 12-18) signaling pathways, both important intermediaries in the cascades controlling cell growth and apoptosis (2, 19-26). Contrary to the other PKCs, the atypicals are insensitive to diacylglycerol and 12-O-tetradecanoylphorbol-13-acetate but have been proposed to be regulated by ceramide (18, 27, 28), phosphatidylinositol 3-kinase (10, 29-34), and Ras (8, 35, 36). In addition, the aPKCs selectively bind to, and are regulated, by two novel proteins (LIP and Par-4) which seem to be critical components of pathways controlling cell growth and survival. Thus, LIP (for lambda /iota PKC-interacting protein) potently induces NF-kappa B in a lambda /iota PKC-dependent manner (14), whereas Par-4 is a potent inhibitor of the atypical PKC enzymatic activity and, interestingly, was initially identified by differential screening in cells that were undergoing growth arrest and apoptosis (3, 37). Consistently, the ectopic expression of Par-4 in NIH-3T3 cells induces apoptosis in a manner that is dependent on its ability to block the atypical PKCs (2, 3). Recent studies demonstrate that the expression of Par-4 sensitizes prostate cancer and melanoma cells to apoptotic stimuli (38), as well as that it may be a mediator of neuronal apoptosis (39). Overexpression of the atypical PKCs inhibits UV- and drug-induced apoptosis in NIH-3T3 (2, 3) and human leukemia cells (5), respectively. Taken together, these results indicate that the aPKCs are potent anti-apoptotic kinases that can be inactivated by pro-apoptotic regulators such as Par-4.

The activation of the caspase system is a critical event in apoptosis (40-42), and recent studies demonstrate that a number of signal transduction kinases are subjected to a caspase-mediated breakdown (43). Early work reported that the degradation of delta PKC by caspase-3 generates an active fragment corresponding to its catalytic domain (44), suggesting that delta PKC activity may be important during apoptotic cell death (45). Consistently, inhibition of delta PKC impairs UV-induced apoptosis in keratinocytes (46). MEKK-1 is also cleaved during apoptosis by anoikis (47), Fas ligation (48), and genotoxic stress (49). In all three cases, the caspase-mediated degradation of MEKK-1 produced a catalytically active fragment, in keeping with the pro-apoptotic properties of MEKK-1 (47-49). PKN is another example of a kinase degraded by the caspase system producing a catalytically active fragment (50). However, other kinases, such as Raf-1 and Akt are inactivated by proteolytic degradation by the caspase system during apoptosis (43). This is particularly relevant because both Raf-1 and Akt are anti-apoptotic kinases (50-56). Therefore, a model is emerging whereby the activation of caspases in apoptotic cells leads to the cleavage of different kinases with opposite outcomes, depending on whether the given kinase plays a pro- or an anti-apoptotic role. Because the aPKCs control pro-survival signals, in the study reported here we have addressed the potential degradation of the atypical PKCs by the caspase system in HeLa cells exposed to UV irradiation.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Plasmids-- pCDNA3-zeta PKCmyc containing the full-length rat zeta PKC with the Myc tag at the COOH terminus was obtained by polymerase chain reaction. pCDNA3-Myc-lambda /iota PKC and pCDNA3-GST-zeta PKCDEL (residues 240-592) constructs were tagged with the Myc epitope or with the GST protein at the amino terminus, respectively. The corresponding fragments excised from pCDNA3-HA-lambda /iota PKC and pCDNA3-HA-zeta PKCDEL, respectively (6), were subcloned into pCDNA3-Myc or pCDNA3-GST. The zeta PKC caspase mutants were obtained by site-directed mutagenesis (Quick change, Stratagene): zeta PKC1, D200G; zeta PKC2, D210G; zeta PKC3, D239G; zeta PKC1/2, DD200/210GG; zeta PKC2/3, DD210/239GG; zeta PKC1/2/3, DDD200/210/239GGG.

Cell Culture, Transfections, and Reagents-- HeLa cells were maintained in high glucose Dulbecco's modified Eagle's medium containing 10% fetal calf serum, 100 µg/ml penicillin G, and 100 µg/ml streptomycin (FLOW). Subconfluent cells were transfected by the calcium phosphate method (CLONTECH, Inc.). Some experiments were performed in the presence of the ICE inhibitors YVAD-CHO, DEVD-CHO, or z-VAD-fmk (Bachem, United Kingdom). For UV treatment, culture medium was removed, dishes were washed once with phosphate-buffered saline, UVC irradiated (180 J/m2), and fresh medium was added to the cells. The monoclonal anti-lambda /iota PKC was from Transduction Laboratories. Anti-Myc epitope (9E10) antibody was from UBI.

aPKC Activity-- HeLa cells incubated at different times after UV light exposure were extracted with lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% Triton X-100, 2 mM EDTA, 1 mM EGTA, and protease inhibitors) and immunoprecipitated with a monoclonal anti-lambda /iota PKC. Immunoprecipitates were washed seven times with lysis buffer containing 0.5 M NaCl. For in vitro kinase assay, immunocomplexes were incubated with 1 µg of myelin basic protein and 5-10 µCi (100 µM) of [gamma -32P]ATP in kinase buffer (35 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 0.5 mM EGTA, 0.1 mM CaCl2, 1 mM phenyl phosphate) for 30 min at 30 °C in a final volume of 20 µl. Reactions were stopped by the addition of concentrated sample buffer. Samples were boiled for 3 min and separated by SDS-polyacrylamide gel electrophoresis (PAGE) followed by exposure and quantitation in an InstantImager (Packard). The activity of transfected Myc-zeta PKC was determined in immunoprecipitates with an anti-Myc antibody (9E10, UBI) as described above.

In Vitro Protease Assays-- Wild-type zeta PKC and the different mutants were translated in vitro using a coupled transcription and translation system with T7 polymerase (Promega, Madison, WI). Apoptotic cells extract was prepared as follows. HeLa cells were UV-irradiated for 10 h, washed once in ice-cold phosphate-buffered saline, and resuspended at 2 × 108/ml in lysis buffer (25 mM HEPES, pH 7.5, 5 mM EDTA, 2 mM dithiothreitol, 0.1% CHAPS, 10% sucrose, and 1 mM phenylmethylsulfonyl fluoride). The lysate was then subjected to four freeze-thaw cycles prior to centrifugation at 10,000 × g for 10 min. Recombinant caspase-3 was from Pharmingen. Cell extracts, in the absence or presence of caspase inhibitors (10 nM; YVAD-CHO or DEVD-CHO), or purified caspase-3 were incubated for 1 h at 37 °C with 5 µl of 35S-labeled in vitro translated wild-type or mutant zeta PKC. The reaction was stopped by addition of Laemmli sample buffer and subjected to SDS-PAGE prior to drying and exposure in an InstantImager (Packard).

Apoptosis Assays-- beta -Galactosidase co-transfection assays for determination of cell death were performed as described (2, 3). TUNEL analysis was performed using the "in situ cell death detection kit" (Boehringer Mannheim).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

We initially determined the effect of UV irradiation on the activity and potential cleavage of lambda /iota PKC and zeta PKC during apoptosis. HeLa cells were UV-irradiated for different times, after which endogenous lambda /iota PKC was immunoprecipitated and its activity was determined. Parallel extracts were analyzed by immunoblot. Results of Fig. 1A demonstrate that short exposures (5-20 min) to UV irradiation provokes a measurable activation of lambda /iota PKC activity. However, longer treatments leads to a robust reduction of lambda /iota PKC activity to below basal levels, that is detectable at 2 h, and maximal at 4-20 h. Immunoblot analysis reveals that the protein levels of lambda /iota PKC remain unchanged at all the time points measured. Identical results were obtained when this experiment was performed in HeLa cells that have been transfected with a Myc-tagged lambda /iota PKC construct and in which the activity and levels of the enzyme were determined with an anti-Myc antibody (not shown). Because there are not reliable antibodies selective for the zeta PKC isoform, we next transfected HeLa cells with a Myc-tagged version of zeta PKC after which cells were UV-irradiated as above. Results of Fig. 1B show that, in contrast to lambda /iota PKC, short-term irradiation does not affect zeta PKC activity. However, longer exposures to UV light produces a dramatic reduction on zeta PKC activity that precedes its proteolytic degradation that produces a fragment of approximately 50 kDa. Because this zeta PKC construct was Myc-tagged at the COOH terminus, this fragment must include the catalytic domain. Therefore, the anti-Myc immunoprecipitates contained not only the full-length protein but also the fragments generated by UV irradiation (not shown). The fact that the enzymatic activity is reduced in UV-irradiated cells indicates that the zeta PKC 50-kDa fragment generated by UV irradiation is catalytically inactive. TUNEL analysis of parallel cultures indicated that apoptosis becomes detectable at 10 h. At this time point, 12 ± 2% of the cells showed signs of DNA fragmentation. At 20 h, the number of apoptotic cells increased to 30 ± 10%, whereas at 40 h, virtually all cells were apoptotic.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 1.   Activity and levels of the atypical PKC isotypes in UV-irradiated cells. A, HeLa cell extracts were prepared at different times following UV-irradiation, after which the levels of lambda /iota PKC were determined by immunoblot with a monoclonal lambda /iota PKC-specific antibody (upper panel). This is a representative experiment of three with identical results. Parallel extracts were immunoprecipitated with the same antibody, and the activity of lambda /iota PKC was determined as described under "Materials and Methods" (lower panel). Results are the mean ± S.D. of four independent experiments including the one shown in the upper panel. B, extracts from HeLa cells transfected with a COOH-terminal Myc-tagged version of zeta PKC were prepared at different times following UV irradiation, after which the levels of zeta PKC were determined by immunoblot with a monoclonal anti-Myc antibody (upper panel). This is a representative experiment of three with very similar results. Parallel extracts were immunoprecipitated with the same antibody, and the activity of zeta PKC was determined as described under "Materials and Methods" (lower panel). Results are the mean ± S.D. of four independent experiments including the one shown in the upper panel.

In the next series of experiments the involvement of the caspase system in the degradation of zeta PKC was determined. Thus, HeLa cells transfected with Myc-tagged zeta PKC were UV-irradiated either in the absence or presence of z-VAD, a broad-specific inhibitor of caspases, and the activity and degradation of zeta PKC was determined. Results of Fig. 2A demonstrate that the presence of z-VAD completely abrogated the UV-induced cleavage of zeta PKC with little or no effect on its inhibition. Of note, the presence of z-VAD did not affect the changes in activity of lambda /iota PKC produced by UV irradiation (Fig. 2B). Collectively these results indicate that zeta PKC is degraded by a caspase-mediated process during UV irradiation but that its inhibition is caspase-independent.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of z-VAD on the inhibition of the atypical PKC activity by UV irradiation. A, HeLa cells transfected with the COOH-terminal Myc-tagged version of zeta PKC were incubated or not with z-VAD prior to UV irradiation. Afterward cell extracts were prepared at different times following UV irradiation and the levels of zeta PKC were determined by immunoblot with the monoclonal anti-Myc antibody (upper panel). This is a representative experiment of three with very similar results. Parallel extracts were immunoprecipitated with the same antibody, and the activity of zeta PKC was determined as described under "Materials and Methods" (lower panel). Results are the mean ± S.D. of four independent experiments including the one shown in the upper panel. HeLa cells were incubated or not with z-VAD prior to UV irradiation. Afterward cell extracts were prepared at different times following UV irradiation and the levels of lambda /iota PKC were determined by immunoblot with the monoclonal anti-lambda /iota PKC antibody (upper panel). This is a representative experiment of three with very similar results. Parallel extracts were immunoprecipitated with the same antibody, and the activity of lambda /iota PKC was determined as described under "Materials and Methods" (lower panel). Results are the mean ± S.D. of four independent experiments including the one shown in the upper panel.

To further explore the possible breakdown of zeta PKC by caspases, 35S-labeled in vitro translated zeta PKC or lambda /iota PKC were incubated in vitro with extracts from cell cultures that were either untreated or exposed to UV light for 10 h. Interestingly, a fragment of identical size to that produced in vivo and most probably corresponding to the catalytic domain of the enzyme was observed when zeta PKC but not lambda /iota PKC was incubated with extracts from UV-irradiated cells (Fig. 3A). In addition, another fragment of about 20-30 kDa was also detected which most probably corresponds to the regulatory domain of zeta PKC (Fig. 3A). The cleavage of zeta PKC is prevented by the incubation with z-VAD or DEVD, but not by YVAD (Fig. 3B). Because DEVD is relatively specific for caspase-3 whereas YVAD is for caspase-1, these results strongly suggest that zeta PKC may be a substrate of caspase-3. This is confirmed in the results of Fig. 3C demonstrating that recombinant caspase-3 efficiently cleaves zeta PKC but not lambda /iota PKC in vitro.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 3.   Caspase-mediated breakdown of zeta PKC in vitro. 35S-Labeled in vitro translated zeta PKC (A-C) or lambda /iota PKC (A and C) were incubated with extracts from either control or UV-irradiated cells (A and B), either in the absence (A and B) or presence of different caspase inhibitors (B), or with recombinant caspase-3 (C). Afterward the reaction was fractionated by SDS-PAGE followed by autoradiography in an InstantImager. Essentially identical results were obtained in another two experiments.

The size of the zeta PKC fragments generated by the caspase action suggests that the cleavage must occur at the hinge region linking the regulatory and the catalytic domains. In addition, because lambda /iota PKC is resistant to caspase-mediated breakdown, the caspase cleavage site(s) should be present in a region of zeta PKC with no sequence homology with lambda /iota PKC. The hinge domain in the atypical PKCs is, together with the V1 region, where the major differences exist between zeta PKC and lambda /iota PKC (57). Interestingly, the alignment of the hinge regions of zeta PKC and lambda /iota PKC reveals the existence of three potential caspase sites in zeta PKC that are absent in lambda /iota PKC. These sites are underlined in Fig. 4 and named as 1, 2, and 3. In order to determine which of these potential sites are important for zeta PKC breakdown, different zeta PKC mutants that abrogate the caspase consensus sequence were constructed, translated in vitro, and incubated with extracts from UV-irradiated cells. The individual disruption of sites 1, 2, and 3, produced no effect on the degradation of zeta PKC (Fig. 5). However, although the double 1/2 mutant was also cleaved, the 2/3 and 1/2/3 mutants were completely resistant to degradation (Fig. 5). This indicates that sites 2 and 3 are the targets of the caspase-mediated breakdown of zeta PKC. In order to explore the role of sites 2 and 3 in vivo, Myc-tagged zeta PKC2/3 mutant (myc-zeta PKC2/3) was transfected into HeLa cells, after which they were UV-irradiated for different times and the activity and levels of this zeta PKC mutant were determined. Results of Fig. 6 demonstrate that although myc-zeta PKC2/3 is completely resistant to degradation, its enzymatic activity is dramatically inhibited by UV irradiation.


View larger version (8K):
[in this window]
[in a new window]
 
Fig. 4.   Alignment of the hinge region of zeta PKC and lambda /iota PKC. The putative caspase sites in the zeta PKC sequence are underlined and named 1, 2, and 3.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of mutations of the caspase sites on the cleavage of zeta PKC. 35S-Labeled in vitro translated zeta PKC, wild type (WT), or mutated at the different caspase sites as described under "Materials and Methods," was incubated with extracts from either control or UV-irradiated cells. Afterward the reaction was fractionated by SDS-PAGE followed by autoradiography in an InstantImager. Essentially identical results were obtained in another two experiments.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 6.   Mutation of the caspase sites does not affect the inhibition of zeta PKC activity by UV irradiation. Extracts from HeLa cells transfected with a Myc-tagged zeta PKC2/3 mutant were prepared at different times following UV irradiation, after which the levels of zeta PKC2/3 were determined by immunoblot with a monoclonal anti-Myc antibody (upper panel). This is a representative experiment of three with very similar results. Parallel extracts were immunoprecipitated with the same antibody, and the activity of zeta PKC2/3 was determined as described under "Materials and Methods" (lower panel). Results are the mean ± S.D. of four independent experiments including the one shown in the upper panel.

Collectively these findings indicate that UV irradiation inhibits both lambda /iota PKC and zeta PKC activities. This is consistent with previous data from this laboratory and may be due to the interaction of these PKCs with the selective protein inhibitor Par-4 (2, 3). A previously unreported observation is the degradation of zeta PKC mediated by caspase-3. This generates a fragment that is identical to the catalytic domain of zeta PKC, that should be permanently active because it lacks the regulatory region which keeps the enzyme blocked through the binding of the catalytic domain to the pseudosubstrate sequence (57). However, the data presented in this study (Fig. 1B), suggest that the catalytic fragment generated by UV irradiation is inactive, since at 20 h its enzymatic activity still is inhibited despite the fact that all the zeta PKC has been broken-down to its catalytic fragment. To more firmly demonstrate this possibility, HeLa cells were transfected with a GST-tagged version of the catalytic domain of zeta PKC (GST-zeta PKCCAT) encompassing residues from site 3 to the end of the protein. Afterward, cells transfected with the catalytic zeta PKC were UV irradiated for different times, and the levels and activity of the GST-zeta PKCCAT construct were determined. Results of Fig. 7 demonstrate that UV irradiation produces a robust inhibition of the catalytic construct, indicating that some signal is generated by this stress treatment that not only inhibits the full-length protein, as previously reported (2) and shown in Fig. 1B, but also the catalytic fragment that is generated during the UV-irradiation process.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 7.   UV irradiation inhibits the activity of catalytic zeta PKC. Extracts from HeLa cells transfected with a GST-tagged version of the zeta PKCCAT construct were prepared at different times following UV irradiation, after which the levels of zeta PKCCAT were determined by immunoblot with a monoclonal anti-GST antibody (upper panel). This is a representative experiment of three with very similar results. Parallel extracts were immunoprecipitated with the same antibody, and the activity of zeta PKCCAT was determined as described under "Materials and Methods" (lower panel). Results are the mean ± S.D. of four independent experiments including the one shown in the upper panel.

The results of Table I demonstrate that the cleavage of zeta PKC by caspase-3 is a critical event for apoptosis. To address this, we used a beta -galactosidase cell viability assay. HeLa cells were transfected with either a control expression vector or plasmids for wild-type or caspase-resistant zeta PKC, after which the cultures were UV-irradiated and the number of beta -galactosidase-positive (blue) cells were scored 36 h thereafter. Interestingly, the expression of caspase-resistant zeta PKC protected HeLa cells from UV-induced apoptosis more efficiently than the wild-type enzyme (Table I). These results suggest that the caspase-mediated cleavage of zeta PKC significantly contributes to apoptotic cell death.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Enhanced protection from UV-induced apoptosis by the caspase-resistant zeta PKC mutant
HeLa cells were transfected with pCMV-beta gal (2.5 µg) and either 2 or 10 µg of either plasmid control pCDNA3 (control) or expression vectors for wild-type (zeta PKC) or caspase-resistant (zeta PKC2/3) zeta PKC. Twenty-four h post-transfection cells were induced to undergo apoptosis by UV irradiation and 36 h later they were fixed and stained with 5-bromo-4-chloro-3-indoyl beta -D-galactoside. Results (number of blue cells per 35-mm dish) are the mean ± S.D. of three independent experiments with incubations in duplicate. Statistical differences from control untreated cell cultures.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Caspase activation is a critical and ultimate step in apoptotic cell death. A number of substrates have been reported to be the target of these proteolytic enzymes (40-42). Among those, considerable attention has recently been focused on the caspase-mediated degradation of enzymes involved in cell growth and survival. Thus, the caspase-mediated cleavage seems to trigger the activation of pro-apoptotic kinases, such as MEKK-1 or PKN (46-49), and the inactivation of anti-apoptotic or proliferative kinases, such as Raf-1 or Akt (43). Regarding PKC, the delta  isoform has been shown to be cleaved by caspases, which results in the generation of a catalytically active fragment (44, 45). This suggests that delta PKC activation by proteolytic degradation may be considered a critical step in apoptosis. Actually, expression of the catalytic fragment of delta PKC is sufficient to induce programmed cell death (44, 45).

In this study we demonstrate a differential regulation of zeta PKC and lambda /iota PKC during UV-induced apoptosis. Thus, lambda /iota PKC is stimulated at early times after UV-irradiation whereas zeta PKC is not (Fig. 1). Recent studies from this laboratory show that lambda /iota PKC can be selectively activated by the novel regulator LIP (14). It is possible that an increased interaction with this protein after UV irradiation may account for the selective activation of lambda /iota PKC by this stress stimulus.2 Perhaps more interesting from the point of view of the role of the atypical PKCs in apoptosis, is our observation that both aPKCs are inhibited in UV-irradiated cells, but that only zeta PKC is proteolytically cleaved. This cleavage seems to be produced by the direct action of caspase-3 on two sites in the hinge region of zeta PKC. However, although the degradation of zeta PKC generates a fragment that under normal conditions is more active than the full-length protein, in UV-irradiated cells this fragment is completely inactive. This is in marked contrast to what has been reported for delta PKC and is in keeping with the notion that zeta PKC is a pro-survival enzyme that needs to be blocked for apoptosis to proceed (1-3, 44, 45). The observation that a caspase-resistant mutant of zeta PKC protects cells from apoptosis more efficiently than the wild-type enzyme, indicates that the proteolytic degradation of zeta PKC is an additional and critical way to modulate UV-induced apoptosis in HeLa cells contributing to the inevitability of the apoptotic cell death. We have previously shown that Par-4 induction during UV irradiation is a mechanism for the inactivation of the atypical PKCs (2, 3). However, Par-4 cannot interact with the catalytic domain of those kinases (3); therefore, the inhibition of the enzymatic activity of the catalytic fragment in the UV-irradiated cells, detected in this study, indicates that mechanisms in addition to the binding of Par-4 to the regulatory domain must operate for the blockage of zeta PKC during apoptosis. These mechanisms will probably target the catalytic domain of the kinase, but its precise nature remains to be determined. However, we are tempted to speculate that the activation of phosphatases may promote the de-phosphorylation of critical residues in the activation loop of zeta PKC that are required for its basal activity (58,59). These residues have been reported to be phosphorylated by PDK-1, a phosphatidylinositol 3-kinase-dependent enzyme (30, 31). Although there is no published evidence that phosphatidylinositol 3-kinase is inactivated in UV-irradiated HeLa cells, it is blocked in other forms of apoptosis, such as in anoikis (56), in ceramide-treated cells (60), or following genotoxic stress (61). Therefore, it is possible that the inactivation of phosphatidylinositol 3-kinase by stress leads to the de-phosphorylation of residues important in the activation loop of zeta PKC which, together with the binding of Par-4, may be the critical events on its inhibition.

    ACKNOWLEDGEMENTS

We are indebted to Esther Garcia, Carmen Ibañez, and Beatriz Ranera for technical assistance and Gonzalo Paris and Isabel Perez for help and enthusiasm.

    FOOTNOTES

* This work was supported by Grants SAF96-0216 from Comisión Interministerial de Ciencia y Tecnología, Spain, PM96-0002-C02 from Dirección General de Investigación Científica y Técnica (DGICYT), and BIO4-CT97-2071 from the European Union, and by funds from Glaxo Wellcome Spain, and an institutional grant from Fundación Ramón Areces to the Centro de Biologia Molecular.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Universidad Autónoma, Canto Blanco, 28049 Madrid, Spain. Tel.: 34-913978039; Fax: 34-629690055; E-mail: tdiazmeco{at}cbm.uam.es.

2 L. Sanz, M. T. Diaz-Meco, and J. Moscat, unpublished observations.

    ABBREVIATIONS

The abbreviations used are: PKC, protein kinase C; aPKC, atypical protein kinase C; ERK, extracellular signal-regulated kinase; GST, glutathione S-transferase; LIP, lambda /iota PKC interacting protein; MAPK, mitogen-activated protein kinase; MEKK, MAPK kinase kinase; NF-kappa B, nuclear factor kappa B; PAGE, polyacrylamide gel electrophoresis; Par-4, prostate apoptosis response 4; PDK-1, phosphoinositide-dependent protein kinase-1; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
  1. Berra, E., Diaz-Meco, M. T., Dominguez, I., Municio, M. M., Sanz, L., Lozano, J., Chapkin, R. S., and Moscat, J. (1993) Cell 74, 555-563[Medline] [Order article via Infotrieve]
  2. Berra, E., Municio, M. M., Sanz, L., Frutos, S., Diaz-Meco, M. T., and Moscat, J. (1997) Mol. Cell. Biol. 17, 4346-4354[Abstract]
  3. Diaz-Meco, M. T., Municio, M. M., Frutos, S., Sanchez, P., Lozano, J., Sanz, L., and Moscat, J. (1996) Cell 86, 777-786[Medline] [Order article via Infotrieve]
  4. Dominguez, I., Diaz-Meco, M. T., Municio, M. M., Berra, E., Garcia de Herreros, A., Cornet, M. E., Sanz, L., and Moscat, J. (1992) Mol. Cell. Biol. 12, 3776-3783[Abstract]
  5. Murray, N. E., and Fields, A. P. (1997) J. Biol. Chem. 272, 27521-27524[Abstract/Free Full Text]
  6. Berra, E., Diaz-Meco, M. T., Lozano, J., Frutos, S., Municio, M. M., Sanchez, P., Sanz, L., and Moscat, J. (1995) EMBO J. 14, 6157-6163[Abstract]
  7. Bjorkoy, G., Perander, M., Overvatn, A., and Johansen, T. (1997) J. Biol. Chem. 272, 11557-11565[Abstract/Free Full Text]
  8. Liao, D-F., Monia, B., Dean, N., and Berk, B. C. (1997) J. Biol. Chem. 272, 6146-6150[Abstract/Free Full Text]
  9. Kampfer, S., Hellbert, K., Villunger, A., Doppler, W., Baier, G., Grunicke, H. H., and Uberall, F. (1998) EMBO J. 17, 4046-4055[Abstract/Free Full Text]
  10. Sontag, E., Sontag, J. M., and Garcia, A. (1997) EMBO J. 16, 5662-5671[Abstract/Free Full Text]
  11. Van Dijk, M. C. M., Muriana, F. J. G., van der Hoeven, P. C. J., Widt, J., Schaap, D., Moolenaar, W. H., and van Blitterswijk, W. J. (1997) Biochem. J. 323, 693-699[Medline] [Order article via Infotrieve]
  12. Bjorkoy, G., Overvatn, A., Díaz-Meco, M. T., Moscat, J., and Johansen, T. (1995) J. Biol. Chem. 270, 21299-21306[Abstract/Free Full Text]
  13. Diaz-Meco, M. T., Berra, E., Municio, M. M., Sanz, L., Lozano, J., Dominguez, I., Diaz-Golpe, V., Lain de Lera, M. T., Alcamí, J., Payá, C. V., Arenzana-Seisdedos, F., Virelizier, J. L., and Moscat, J. (1993) Mol. Cell. Biol. 13, 4770-4775[Abstract]
  14. Diaz-Meco, M. T., Municio, M. M., Sanchez, P., Lozano, J., and Moscat, J. (1996) Mol. Cell. Biol. 16, 105-114[Abstract]
  15. Dominguez, I., Sanz, L., Arenzana-Seisdedos, F., Diaz-Meco, M. T., Virelizier, J. L., and Moscat, J. (1993) Mol. Cell. Biol. 13, 1290-1295[Abstract]
  16. Folgueira, L., McElhinny, J. A., Bren, G. D., MacMorran, W. S., Diaz-Meco, M. T., Moscat, J., and Payá, C. V. (1996) J. Virol. 70, 223-231[Abstract]
  17. Huang, C., Ma, W., Bowden, G. T., and Dong, Z. (1996) J. Biol. Chem. 271, 31262-31268[Abstract/Free Full Text]
  18. Lozano, J., Berra, E., Municio, M. M., Diaz-Meco, M. T., Dominguez, I., Sanz, L., and Moscat, J. (1994) J. Biol. Chem. 269, 19200-19202[Abstract/Free Full Text]
  19. Beg, A. A., and Baltimore, D. (1996) Science 274, 782-784[Abstract/Free Full Text]
  20. Cuvillier, O., Pirianov, G., Kleuser, B., Vanek, P. G., Coso, O. A., Gutkind, J. S., and Spiegel, S. (1996) Nature 381, 800-803[CrossRef][Medline] [Order article via Infotrieve]
  21. Gardner, A. M., and Johnson, G. L. (1996) J. Biol. Chem. 271, 14560-14566[Abstract/Free Full Text]
  22. Parrizas, M., Saltiel, A. R., and LeRoith, D. (1997) J. Biol. Chem. 272, 154-161[Abstract/Free Full Text]
  23. Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., and Verma, I. M. (1996) Science 274, 787-789[Abstract/Free Full Text]
  24. Wang, C-Y., Mayo, M. W., and Baldwin, A. S. (1996) Science 274, 784-787[Abstract/Free Full Text]
  25. Wu, M., Lee, H., Bellas, R. E., Schauer, S. L., Arsura, M., Katz, D., Fitzgerald, M. J., Rothstein, T. L, Sherr, D. H., and Sonenshein, G. E. (1996) EMBO J. 15, 4682-4690[Abstract]
  26. Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., and Greenberg, M. E. (1995) Science 270, 1326-1332[Abstract]
  27. Limatola, C., Barabino, B., Nista, A., and Santoni, A. (1997) Biochem. J. 321, 497-501[Medline] [Order article via Infotrieve]
  28. Müller, G., Ayoub, M., Storz, P., Rennecke, J., Fabbro, D., and Pfizenmaier, K. (1995) EMBO J. 14, 1961-1969[Abstract]
  29. Akimoto, K., Takahashi, R., Moriya, S., Nishioka, N., Takayanagi, J., Kimura, K., Fukui, Y., Osada, S-I.,, Mizuno, K., Hirai, S-I., Kazlauskas, A., and Ohno, S. (1996) EMBO J. 15, 788-798[Abstract]
  30. Chou, M. M., Hou, W., Johnson, J., Graham, L. K., Lee, M. H., Chen, C-S., Newton, A. C., Schaffhausen, B. S., and Toker, A. (1998) Curr. Biol. 8, 1069-1077[Medline] [Order article via Infotrieve]
  31. Le Good, J. A., Ziegler, W. H., Parekh, D. B., Alessi, D. R., Cohen, P., and Parker, P. J. (1998) Science 281, 2042-2045[Abstract/Free Full Text]
  32. Mendez, R., Kollmorgen, G., White, M. F., and Rhoads, R. E. (1997) Mol. Cell. Biol. 17, 5184-5192[Abstract]
  33. Nakanishi, H., Brewer, K. A., and Exton, J. H. (1993) J. Biol. Chem. 268, 13-16[Abstract/Free Full Text]
  34. Standaert, M. L., Galloway, L., Karnam, P., Bandyopadhyay, G., Moscat, J., and Farese, R. V. (1997) J. Biol. Chem. 272, 30075-30082[Abstract/Free Full Text]
  35. Diaz-Meco, M. T., Lozano, J., Municio, M. M., Berra, E., Frutos, S., Sanz, L., and Moscat, J. (1994) J. Biol. Chem. 269, 31706-31710[Abstract/Free Full Text]
  36. Wooten, M. W., Seibenhener, M. L., Matthews, L. H., Zhou, G., and Coleman, E. S. (1996) J. Neurochem. 67, 1023-1031[Medline] [Order article via Infotrieve]
  37. Sells, S. F., Wood, D. P., Joshi-Barve, S. S., Muthukumar, S., Jacob, R. J., Crist, S. A., Humphreys, S., and Rangnekar, V. M. (1994) Cell Growth Differ. 5, 457-466[Abstract]
  38. Sells, S. F., Han, S., Muthukkumar, S., Maddiwar, N., Johnstone, R., Boghaert, E., Gillis, D., Liu, G., Nair, P., Monnig, S., Collini, P., Mattson, M. P., Sukhatme, V. P., Zimmer, S. G., Wood, D. P., McRoberts, J. W., Shi, Y., and Rangnekar, V. M. (1997) Mol. Cell. Biol. 17, 3823-3832[Abstract]
  39. Guo, Q., Fu, W., Xie, J., Luo, H., Sells, S. F., Geddes, J. W., Bondada, V., Rangnekar, V. M., and Mattson, M. P. (1998) Nature Gen. 4, 957-962
  40. Ashkenazi, A., and Dixit, V. M. (1998) Science 281, 1305-1308[Abstract/Free Full Text]
  41. Salvesen, G. S., and Dixit, V. M. (1997) Cell 91, 443-446[Medline] [Order article via Infotrieve]
  42. Thornberry, N. A., and Lazebnik, Y. (1998) Science 281, 1312-1316[Abstract/Free Full Text]
  43. Widmann, C., Gibson, S., and Johnson, G. L. (1998) J. Biol. Chem. 273, 7141-7147[Abstract/Free Full Text]
  44. Emoto, Y., Manome, Y., Meinhardt, G., Kisaki, H., Kharbanda, S., Robertson, M., Ghayur, T., Wong, W. W., Kamen, R., Weichselbaum, R., and Kufe, D. (1995) EMBO J. 14, 6148-6156[Abstract]
  45. Ghayur, T., Hugunin, M., Talanian, R. V., Ratnofsky, S., Quinlan, C., Emoto, Y., Pandey, P., Datta, R., Kharbanda, S., Allen, H., Kamen, R., Wong, W., and Kufe, D. (1996) J. Exp. Med. 184, 2399-2404[Abstract/Free Full Text]
  46. Denning, M. F., Wang, Y., Nickoloff, B. J., and Wrone-Smith, T. (1998) J. Biol. Chem. 273, 29995-30002[Abstract/Free Full Text]
  47. Cardone, M. H., Salvesen, G. S., Widmann, C., Johnson, G., and Frisch, S. M. (1997) Cell 90, 315-323[Medline] [Order article via Infotrieve]
  48. Deak, J. C., Cross, J. V., Lewis, M., Qian, Y., Parrot, L. A., Distelhorst, C. W., and Templeton, D. J. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 5595-5600[Abstract/Free Full Text]
  49. Widmann, C., Gerwins, P., Johnson, N. L., Jarpe, M. B., and Johnson, G. L. (1998) Mol. Cell. Biol. 18, 2416-2429[Abstract/Free Full Text]
  50. Takahashi, M., Mukai, H., Toshimori, M., Miyamoto, M., and Ono, Y. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 11566-11571[Abstract/Free Full Text]
  51. Berra, E., Diaz-Meco, M. T., and Moscat, J. (1998) J. Biol. Chem. 273, 10792-10797[Abstract/Free Full Text]
  52. Hemmings, B. A. (1997) Science 275, 628-630[Free Full Text]
  53. Kaufmann-Zeh, A., Rodriguez-Viciana, P., Ulrich, E., Gilbert, C., Coffer, P., Downward, J., and Evan, G. (1997) Nature 385, 544-548[CrossRef][Medline] [Order article via Infotrieve]
  54. Kulik, G. A., Klippel, A., and Weber, M. J. (1997) Mol. Cell. Biol. 17, 1595-1606[Abstract]
  55. Wang, H-G., Rapp, U. R., and Reed, J. C. (1996) Cell 87, 629-638[Medline] [Order article via Infotrieve]
  56. Khwaja, A., Rodriguez-Viciana, P., Wennstrom, S., Warne, P. H., and Downward, J. (1997) EMBO J. 16, 2783-2793[Abstract/Free Full Text]
  57. Nishizuka, Y. (1992) Science 258, 607-614[Medline] [Order article via Infotrieve]
  58. Orr, J. W., and Newton, A. C. (1994) J. Biol. Chem. 269, 27715-27718[Abstract/Free Full Text]
  59. Newton, A. C. (1997) Curr. Opin. Cell Biol. 9, 161-167[CrossRef][Medline] [Order article via Infotrieve]
  60. Zundel, W., and Garcia, A. (1998) Genes Dev. 12, 1941-1946[Abstract/Free Full Text]
  61. Yuan, Z. M., Utsugisawa, T., Huang, Y., Ishiko, T., Nakada, S., Kharbanda, S., Weichselbaum, R., and Kufe, D. (1997) J. Biol. Chem. 272, 23485-23488[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.